Systematic review of Farnesoid X Receptor (FXR) as a therapeutic target in diabetic cardiomyopathy and cardiometabolic diseases

American Heart Journal Plus: Cardiology Research and Practice · Elsevier

The publisher did not provide an abstract — full text is available via the link below.

Read at publisher →

Similar articles